Tumor immune microenvironment remodeling predicts response to checkpoint inhibitor therapy
Authors:
- Zhongyang LinZLZhongyang Lin
- Mitalee ChandraMCMitalee Chandra
- Nalini SrinivasNSNalini Srinivas
- Selma UgurelSUSelma Ugurel
- Jürgen C. BeckerJBJürgen C. Becker
- Dvir AranDADvir Aran
- 1 September 2026
- journal article
- Published by Elsevier in Cancer Cell
- Vol. 44 (9) , 1847-1861.e6
Abstract
No abstract availableFunding Information
- Israel Science Foundation (1543/21)
- Medizinische Fakultät, Universität Duisburg-Essen
- Azrieli Foundation
- Deutschen Konsortium für Translationale Krebsforschung (ED03)
- Else Kröner-Fresenius-Stiftung (EFKS)
This publication has 75 references indexed in Scilit:
- Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancerCancer Cell, 2024
- Single-cell and spatial profiling identify three response trajectories to pembrolizumab and radiation therapy in triple negative breast cancerCancer Cell, 2024
- Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancerCancer Cell, 2023
- Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancerCancer Cell, 2023
- Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancerCancer Cell, 2022
- Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancerCancer Cell, 2021
- Conserved pan-cancer microenvironment subtypes predict response to immunotherapyCancer Cell, 2021
- Progressive immune dysfunction with advancing disease stage in renal cell carcinomaCancer Cell, 2021
- Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsCancer Immunology, Immunotherapy, 2021
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined TherapyCancer Cell, 2019